Logo image of ENSC

ENSYSCE BIOSCIENCES INC (ENSC) Stock Fundamental Analysis

NASDAQ:ENSC - Nasdaq - US2936025046 - Common Stock - Currency: USD

2.18  -0.08 (-3.54%)

Fundamental Rating

4

ENSC gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 560 industry peers in the Biotechnology industry. While ENSC seems to be doing ok healthwise, there are quite some concerns on its profitability. ENSC is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ENSC had negative earnings in the past year.
ENSC had a negative operating cash flow in the past year.
In the past 5 years ENSC reported 4 times negative net income.
In the past 5 years ENSC always reported negative operating cash flow.
ENSC Yearly Net Income VS EBIT VS OCF VS FCFENSC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

1.2 Ratios

ENSC has a Return On Assets of -147.79%. This is amonst the worse of the industry: ENSC underperforms 84.64% of its industry peers.
Looking at the Return On Equity, with a value of -223.55%, ENSC is doing worse than 69.11% of the companies in the same industry.
Industry RankSector Rank
ROA -147.79%
ROE -223.55%
ROIC N/A
ROA(3y)-319.99%
ROA(5y)-221.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ENSC Yearly ROA, ROE, ROICENSC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 5K 10K 15K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ENSC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENSC Yearly Profit, Operating, Gross MarginsENSC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for ENSC has been increased compared to 1 year ago.
ENSC has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, ENSC has an improved debt to assets ratio.
ENSC Yearly Shares OutstandingENSC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ENSC Yearly Total Debt VS Total AssetsENSC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

ENSC has an Altman-Z score of -40.73. This is a bad value and indicates that ENSC is not financially healthy and even has some risk of bankruptcy.
ENSC's Altman-Z score of -40.73 is on the low side compared to the rest of the industry. ENSC is outperformed by 92.32% of its industry peers.
There is no outstanding debt for ENSC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -40.73
ROIC/WACCN/A
WACCN/A
ENSC Yearly LT Debt VS Equity VS FCFENSC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

ENSC has a Current Ratio of 2.50. This indicates that ENSC is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ENSC (2.50) is worse than 69.82% of its industry peers.
A Quick Ratio of 2.50 indicates that ENSC has no problem at all paying its short term obligations.
ENSC has a worse Quick ratio (2.50) than 68.04% of its industry peers.
Industry RankSector Rank
Current Ratio 2.5
Quick Ratio 2.5
ENSC Yearly Current Assets VS Current LiabilitesENSC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.98% over the past year.
The Revenue has grown by 255.53% in the past year. This is a very strong growth!
Measured over the past years, ENSC shows a quite strong growth in Revenue. The Revenue has been growing by 13.86% on average per year.
EPS 1Y (TTM)42.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.15%
Revenue 1Y (TTM)255.53%
Revenue growth 3Y13.86%
Revenue growth 5YN/A
Sales Q2Q%331.69%

3.2 Future

ENSC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 87.91% yearly.
ENSC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 176.07% yearly.
EPS Next Y25.67%
EPS Next 2Y87.91%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-34.94%
Revenue Next 2Y210.46%
Revenue Next 3Y176.07%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ENSC Yearly Revenue VS EstimatesENSC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
ENSC Yearly EPS VS EstimatesENSC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 -1K -2K -3K

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ENSC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 0.11 indicates a rather cheap valuation of ENSC.
ENSC's Price/Forward Earnings ratio is rather cheap when compared to the industry. ENSC is cheaper than 99.82% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.10, ENSC is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 0.11
ENSC Price Earnings VS Forward Price EarningsENSC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENSC Per share dataENSC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

ENSC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ENSC's earnings are expected to grow with 87.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y87.91%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ENSC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENSYSCE BIOSCIENCES INC

NASDAQ:ENSC (5/29/2025, 2:18:21 PM)

2.18

-0.08 (-3.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-12 2025-08-12
Inst Owners15.34%
Inst Owner Change150.78%
Ins Owners1.17%
Ins Owner Change0%
Market Cap5.17M
Analysts82.86
Price Target47.66 (2086.24%)
Short Float %9.33%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)25.42%
Min EPS beat(2)-3.95%
Max EPS beat(2)54.8%
EPS beat(4)3
Avg EPS beat(4)54.7%
Min EPS beat(4)-3.95%
Max EPS beat(4)123.26%
EPS beat(8)6
Avg EPS beat(8)36.07%
EPS beat(12)9
Avg EPS beat(12)35.45%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-10.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.78%
EPS NY rev (1m)0%
EPS NY rev (3m)23.53%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.11
P/S 0.83
P/FCF N/A
P/OCF N/A
P/B 1.69
P/tB 1.69
EV/EBITDA N/A
EPS(TTM)-6.54
EYN/A
EPS(NY)20.52
Fwd EY941.16%
FCF(TTM)-2.45
FCFYN/A
OCF(TTM)-2.45
OCFYN/A
SpS2.63
BVpS1.29
TBVpS1.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -147.79%
ROE -223.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-319.99%
ROA(5y)-221.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover1.35
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.5
Quick Ratio 2.5
Altman-Z -40.73
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.15%
EPS Next Y25.67%
EPS Next 2Y87.91%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)255.53%
Revenue growth 3Y13.86%
Revenue growth 5YN/A
Sales Q2Q%331.69%
Revenue Next Year-34.94%
Revenue Next 2Y210.46%
Revenue Next 3Y176.07%
Revenue Next 5YN/A
EBIT growth 1Y31.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-209.36%
EBIT Next 3Y51.15%
EBIT Next 5YN/A
FCF growth 1Y67.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y67.88%
OCF growth 3YN/A
OCF growth 5YN/A